PMID- 33080725
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 42
DP  - 2020 Oct 16
TI  - The therapeutic efficacy of Huashi Baidu Formula combined with antiviral drugs in 
      the treatment of COVID-19: A protocol for systematic review and meta-analysis.
PG  - e22715
LID - 10.1097/MD.0000000000022715 [doi]
LID - e22715
AB  - BACKGROUND: The Corona Virus Disease 2019 (COVID-19) is a new acute respiratory 
      infectious disease that has become a major global public health event. In China, 
      the combination of Huashi Baidu Formula (HBF) and antiviral drugs is used in the 
      clinical treatment of severe patients with new coronary pneumonia, but there is 
      still a lack of evidence-based medical evaluation. METHODS: We search for 
      research in PubMed/MEDLINE, China National Knowledge Infrastructure (CNKI), 
      Wanfang Database, VIP Database, Cochrane Library, Embase, China Biomedical 
      Database (CBM), and Chinese Science Citation Database (CSCD). For "Huashi Baidu 
      Formula" and "COVID-19," we screened suitable articles without language 
      restrictions on keywords, and recorded and analyzed the screened literature with 
      RevMan 5.3 and STATA 14.2 software. RESULTS: This systematic review and 
      meta-analysis will evaluate the efficacy and safety of HBF combined with 
      antiviral drugs in the treatment of COVID-19, and provide the rationality of 
      clinical drug application. CONCLUSION: Our findings will provide references for 
      clinical diagnosis and treatment and guidance programs for COVID-19. INPLASY 
      REGISTRATION NUMBER: INPLASY202080098.
FAU - Han, Lizhu
AU  - Han L
AD  - College of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China.
FAU - Wang, Yunlan
AU  - Wang Y
FAU - Hu, Kunxia
AU  - Hu K
FAU - Tang, Zhishu
AU  - Tang Z
FAU - Song, Xiao
AU  - Song X
AUID- ORCID: 0000-0003-2172-756
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antiviral Agents)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (huashi baidu)
SB  - IM
MH  - Antiviral Agents/administration & dosage/*therapeutic use
MH  - Betacoronavirus
MH  - COVID-19
MH  - Coronavirus Infections/*drug therapy
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Humans
MH  - Pandemics
MH  - Pneumonia, Viral/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - SARS-CoV-2
MH  - COVID-19 Drug Treatment
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7571870
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/10/22 06:00
MHDA- 2020/11/11 06:00
PMCR- 2020/10/16
CRDT- 2020/10/21 01:01
PHST- 2020/10/21 01:01 [entrez]
PHST- 2020/10/22 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2020/10/16 00:00 [pmc-release]
AID - 00005792-202010160-00058 [pii]
AID - MD-D-20-08836 [pii]
AID - 10.1097/MD.0000000000022715 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Oct 16;99(42):e22715. doi: 
      10.1097/MD.0000000000022715.